ondansetron has been researched along with Infarct in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Na, S | 1 |
| Jung, DE | 1 |
| Hwang, E | 1 |
| Kim, T | 1 |
1 other study available for ondansetron and Infarct
| Article | Year |
|---|---|
Area postrema syndrome caused by medullary infarction.
Topics: Area Postrema; Female; Humans; Infarction; Metoclopramide; Nausea; Ondansetron; Syndrome; Vomiting | 2022 |